Objective
More than forty million middle-aged and elderly EU-citizens suffer from urinary voiding disorders, including incontinence and frequent nightly urination, due to multifactor diseases. The overall goal is to establish temporary antidiuresis as an efficient new therapeutic strategy to improve health and quality of life. This will be based on extensive basic, clinical and industrial research of vasopressin-V_2-receptors (VP-V_2R) and kidney function. As necessary new drugs, short-acting VP-V_2R agonists will be developed. Lead compounds exist and test systems will be established to characterise the compounds at the molecular structural level and at the cellular and integrated level. After safety testing lead compounds will be used in initial clinical trials. Such a treatment will provide symptom relief for these very common life-disrupting disorders with improved health and life quail for this very large group of patients.
Call for proposal
Data not availableFunding Scheme
CSC - Cost-sharing contractsCoordinator
8000 AARHUS C
Denmark